Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug

08/31/2021 | 07:02am EDT


© MT Newswires 2021
All news about IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/04IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
MT
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
MT
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives $2.5 Million Tax Incentive from France
MT
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 2,38 M 1,78 M 1,78 M
Net income 2022 -38,7 M -29,0 M -29,0 M
Net cash 2022 82,0 M 61,3 M 61,3 M
P/E ratio 2022 -7,98x
Yield 2022 -
Capitalization 498 M 372 M 372 M
EV / Sales 2022 175x
EV / Sales 2023 22,9x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,59 AUD
Average target price 1,18 AUD
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED40.96%350
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.28%24 952